Sandoz Suggests Coherus’ Cimerli Strategy Was ‘Unsustainable’

Expands On Plans To Withdraw And Reintroduce US Lucentis Biosimilar

 
• By Dave Wallace
  
Sandoz plans to exit and re-enter the market (Shutterstock)

More from Biosimilars

More from Business